Recent IPO GW Pharmaceuticals (GWPH -0.9%) says it's received commercialization approval for its...


Recent IPO GW Pharmaceuticals (GWPH -0.9%) says it's received commercialization approval for its prescription medicine Sativex in Italy. Sativex is a treatment for moderate to severe spasticity in Multiple Sclerosis patients who have not responded adequately to other anti-spasticity medications.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs